Study finds β-blockers may delay onset and slow progression of Huntington's disease, offering potential as a therapeutic strategy Study: β-Blocker Use and Delayed Onset and Progression of ...
Huntington's disease (HD) is a neurological disorder caused by a genetic mutation passed down through families. The disease destroys cells in different parts of the brain, causing symptoms that get ...
A patient in the UK has received a new therapy for Huntington’s disease, which experts hope could slow progression of the fatal illness. Huntington’s is an inherited condition that is caused ...
Opens in a new tab or window Beta-blocker use was tied with slower symptom progression in people with early motor-manifest Huntington's disease. In a people with genetically confirmed premanifest ...
Huntington's disease is a hereditary neurodegenerative disorder caused by an autosomal dominant mutation. The hallmark symptom of Huntington's disease is the presence of progressive chorea ...
The genetic mutation that causes Huntington's disease (HD)—a devastating brain disease that disrupts mobility and diminishes cognitive ability—may also enhance early brain development and play ...
Its potential in Huntington's disease emerged thanks to an AI drug screening platform operated by SOM, which is used to identify existing drugs that can be repurposed for use in new indications.
Novartis NVS has entered into a global license and collaboration agreement with PTC Therapeutics PTCT for the latter’s Huntington's disease candidate to strengthen NVS’ neuroscience pipeline.
Huntington’s disease (HD) causes progressive neurodegeneration ... Rating Scale of 10 and a Barthel Index (BI) of 90 indicating mild disability. Gait disturbances hindered her ability to hike, a ...